DOI: 10.36347/sasjs.2023.v09i02.016

Pages: 138-142

Gastro intestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastro intestinal tract [1] and account for 80 % of all GI tumors. Approximately 30% of GISTs are malignant [2]. Occurring throughout the entirety of the GI tract, GISTs most commonly present in the stomach or small intestine [3], Most GISTs present asymptomatically. They are best identified by computed tomography (CT) scan and most stain positive for CD117 (C- Kit). For localized, resectable tumors, surgical resection remains the cornerstone of treatment. For patients with locally advanced disease, preoperative imatinib can be used to help reduce tumor burden before resection [4]. We report the case of a 48 years old patient who presented a gastric stromal tumor invading the spleen, the pancreas and a portion of the left liver. After 6 months of néo adjuvant Imatinib therapy, the patient has undergone a longitudinal gastrectomy associated with splenectomy caudal pancreatectomy and left hepatectomy in which the evolution was favorable.